Navidea Biopharmaceuticals News

0,2285 $ -4,27% -0,0102 $
In Euro: 0,1960 € | 22.06.18 AMEX | Mehr Kurse »
WKN: A1JSBX
ISIN: US63937X1037
US-Symbol: NAVB
Typ: Aktie

Navidea Biopharmaceuticals News

  
14.06.18 Navidea to Host Moderated Q&A Webcast with Management Businesswire
30.05.18 Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention Businesswire
08.05.18 Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results Businesswire
02.05.18 Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update Businesswire
16.04.18 Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit Businesswire
16.04.18 Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights Businesswire
03.04.18 Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial Businesswire
11.04.14 Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc. PR Newswire
13.08.13 Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc. PR Newswire
03.06.13 SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea Biopharmaceuticals, Inc. PR Newswire
11.09.12 Navidea Biopharmaceuticals-​Aktie: "buy" - Ladenburg Thalmann Aktiencheck
11.09.12 Navidea Biopharmaceuticals-​Aktie: Kursziel gesenkt - Rodman & Renshaw Aktiencheck
22.08.12 Navidea Biopharmaceuticals-​Aktie: "buy" - ThinkEquity Partners Aktiencheck
31.07.12 Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. PR Newswire
23.07.12 Navidea Biopharmaceuticals-​Aktie: vielversprechende Pipeline - Hot Stocks Investor Aktiencheck

Newssuche